BiotechTube

Evolocumab + Statins (Cardiovascular Agents)

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Hyperlipidemias

Conditions

Hyperlipidemias

Trial Timeline

Feb 17, 2021 → Dec 1, 2024

NCT ID
NCT04608474

About Evolocumab + Statins (Cardiovascular Agents)

Evolocumab + Statins (Cardiovascular Agents) is a approved stage product being developed by Amgen for Hyperlipidemias. The current trial status is unknown. This product is registered under clinical trial identifier NCT04608474. Target conditions include Hyperlipidemias.

What happened to similar drugs?

1 of 4 similar drugs in Hyperlipidemias were approved

Approved (1) Terminated (0) Active (3)
✅atorvastatin + atorvastatin + atorvastatinPfizerApproved
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
🔄Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04608474ApprovedUNKNOWN

Competing Products

5 competing products in Hyperlipidemias

See all competitors
ProductCompanyStageHype Score
atorvastatin + atorvastatin + atorvastatinPfizerApproved
43
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SAL003 140 mg + PlaceboShenzhen Salubris PharmaceuticalsPhase 3
40
SLN360 + PlaceboMedpacePhase 1
26
Bempedoic Acid + Ezetimibe + PlacebosEsperion TherapeuticsPhase 3
34